Cubic Pharmaceutical: Pseudoephedrine Mesylate Sustained-Release Tablets and two other products selected for the 12th batch of national centralized procurement.

Lifang Pharmaceuticals announced that its products were selected in the 12th batch of national centralized procurement of medicines. The sales revenue from Doxazosin Mesylate Sustained-Release Tablets for 2025 is 103 million yuan, accounting for 6.66% of the company's total operating income for 2025; in the first quarter of 2026, the sales revenue is 25.3194 million yuan, accounting for 7.09% of the company's total operating income for the first quarter of 2026. Amlodipine Besylate Tablets were approved for market launch on May 19, 2026, and have not yet generated sales revenue. The selection results will be implemented within this year, with the procurement cycle running from the effective date of the selection results until December 31, 2029.